Losartan and Hyperuricemia
Losartan should be continued and is actually the preferred antihypertensive agent in patients with hyperuricemia or gout, as it uniquely lowers serum uric acid levels through its uricosuric effects. 1
Why Losartan is Beneficial in Hyperuricemia
Losartan is the only angiotensin II receptor blocker (ARB) that consistently demonstrates significant uric acid-lowering properties. The mechanism is well-established: losartan inhibits urate transporter 1 (URAT1) in the proximal renal tubule, increasing urinary uric acid excretion and reducing serum uric acid levels 2. This effect has been confirmed across multiple studies, with losartan reducing serum uric acid by approximately 0.44 mg/dL compared to other ARBs 3.
The 2016 EULAR guidelines explicitly recommend losartan as a preferred antihypertensive choice when gout or hyperuricemia coexists with hypertension 1. This recommendation is echoed by the 2012 ACR guidelines, which note that agents with uricosuric effects like losartan can be therapeutically useful as components of a comprehensive urate-lowering strategy 4.
Dosing Recommendations
The standard dosing for losartan in hypertension is:
- Starting dose: 50 mg once daily 5
- Maximum dose: 100 mg once daily as needed for blood pressure control 5
- In hepatic impairment: Start at 25 mg once daily 5
- In volume-depleted patients: Start at 25 mg once daily 5
The uric acid-lowering effect is observed at standard antihypertensive doses (50 mg/day), so no special dosing adjustment is needed specifically for hyperuricemia 2.
Clinical Context and Management Strategy
When to Strongly Consider Losartan:
Patients with hypertension requiring treatment who also have:
Switching strategy: If a patient is on another ARB (candesartan, valsartan, irbesartan, etc.) and has hyperuricemia, switching to losartan provides dual benefit without compromising blood pressure control 3.
Important Caveats:
Losartan is NOT a substitute for dedicated urate-lowering therapy (ULT) in patients with established gout. The guidelines are clear that allopurinol remains first-line ULT, with target serum uric acid <6 mg/dL (360 μmol/L) 1. Losartan's uric acid-lowering effect is modest (approximately 10-15% reduction) and should be viewed as an adjunctive benefit, not primary treatment 7.
Contraindications and Monitoring:
- Do not use in pregnancy (causes fetal toxicity) 5
- Avoid in bilateral renal artery stenosis 8
- Monitor renal function periodically, especially in patients with CKD, as losartan can cause acute renal function deterioration in volume-depleted states 5
- Monitor potassium levels - losartan can cause hyperkalemia, particularly when combined with other potassium-sparing agents 5
- Correct volume or salt depletion before initiating therapy 5
Comparison with Other ARBs
The evidence is definitive that the uric acid-lowering effect is NOT a class effect of ARBs 9. Studies show:
- Losartan: Consistently lowers serum uric acid 9, 7, 2
- Candesartan and valsartan: Neutral or negative effect (may increase uric acid) 9
- Azilsartan: Negative impact (increases uric acid) 9
- Irbesartan: Neutral or possibly mild positive effect 9
Bottom Line Algorithm
For patients with hyperuricemia:
If hypertensive and requiring ARB therapy: Choose losartan as first-line ARB (50-100 mg daily)
If already on a different ARB: Switch to losartan if hyperuricemia is present or gout develops
If on diuretic therapy causing hyperuricemia: Discontinue diuretic if possible; if antihypertensive still needed, use losartan 1, 6
If patient has established gout: Losartan is beneficial but must be combined with appropriate ULT (allopurinol as first-line) to achieve target serum uric acid <6 mg/dL 1
Monitor: Serum uric acid, renal function, and potassium levels after initiating or switching to losartan
Losartan should never be discontinued solely because of hyperuricemia—it is actually therapeutic for this condition.